Similarly to in vitro experiments, tigecycline elevated the LC3 II level, accompanied by the down‐regulation of SQSTM1/p62 in tumour tissue in tigecycline‐treated group (Figure 5D), indicating that autophagy does occur in tigecycline‐treated MM cells in vivo. This evidence concerns the gene SQSTM1 and Miyoshi myopathy.